● Single award · contract
Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of…
A single federal award, with both ends of the trail linked.
$95.6M
total award value
2021
action date
74 mo
period
75A50121C00077
PIID
Description
The Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (Marv) and Sudan Ebolavirus (Sudv) Disease. These Vaccines Are Based on Recombinant Expression of Filovirus Glycoproteins in
Awarding agencyDepartment of Health and Human Services →
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNew York →
CategoryNAICS 541714PSC AN42
Competed?Not recorded✓ from source
Total (exact)$95,592,504
More from Department of Health and Human Services
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
awarded 2022$71.7B
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; anything we compute or infer (corporate parents, districts, competitors) is ≈ inferred and worded carefully, never asserted as fact.